These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23611296)

  • 1. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.
    Rosenberg JB; De BP; Hicks MJ; Janda KD; Kaminsky SM; Worgall S; Crystal RG
    Hum Gene Ther; 2013 Jun; 24(6):595-603. PubMed ID: 23611296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expecting the antinicotine vaccine].
    Didilescu C
    Pneumologia; 2009; 58(3):177-8. PubMed ID: 19817315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity.
    De BP; Pagovich OE; Hicks MJ; Rosenberg JB; Moreno AY; Janda KD; Koob GF; Worgall S; Kaminsky SM; Sondhi D; Crystal RG
    Hum Gene Ther; 2013 Jan; 24(1):58-66. PubMed ID: 23140508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.
    Zhao Z; Powers K; Hu Y; Raleigh M; Pentel P; Zhang C
    Biomaterials; 2017 Apr; 123():107-117. PubMed ID: 28167389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic vaccines for nicotine dependence.
    Maurer P; Bachmann MF
    Curr Opin Mol Ther; 2006 Feb; 8(1):11-6. PubMed ID: 16506520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical development of a vaccine 'against smoking'.
    Cerny EH; Lévy R; Mauel J; Mpandi M; Mutter M; Henzelin-Nkubana C; Patiny L; Tuchscherer G; Cerny T
    Onkologie; 2002 Oct; 25(5):406-11. PubMed ID: 12415193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity.
    Maurer P; Jennings GT; Willers J; Rohner F; Lindman Y; Roubicek K; Renner WA; Müller P; Bachmann MF
    Eur J Immunol; 2005 Jul; 35(7):2031-40. PubMed ID: 15971275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations of Enantiopure Nicotine Haptens Using an Adjuvanting Carrier in Anti-Nicotine Vaccine Development.
    Jacob NT; Lockner JW; Schlosburg JE; Ellis BA; Eubanks LM; Janda KD
    J Med Chem; 2016 Mar; 59(6):2523-9. PubMed ID: 26918428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small "Non-Natural" Peptides.
    Le HT; Fraleigh NL; Lewicky JD; Boudreau J; Dolinar P; Bhardwaj N; Diaz-Mitoma F; Montaut S; Fallahi S; Martel AL
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32178357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical evaluation of a nicotine vaccine within a self-administration behavioral model.
    Moreno AY; Azar MR; Warren NA; Dickerson TJ; Koob GF; Janda KD
    Mol Pharm; 2010 Apr; 7(2):431-41. PubMed ID: 20104903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier.
    Miller KD; Roque R; Clegg CH
    PLoS One; 2014; 9(12):e114366. PubMed ID: 25494044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic vaccines against tobacco addiction.
    Fahim RE; Kessler PD; Kalnik MW
    Expert Rev Vaccines; 2013 Mar; 12(3):333-42. PubMed ID: 23496672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine.
    Zheng H; Hu Y; Huang W; de Villiers S; Pentel P; Zhang J; Dorn H; Ehrich M; Zhang C
    J Biomed Nanotechnol; 2015 Dec; 11(12):2197-210. PubMed ID: 26510313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular attributes of conjugate antigen influence function of antibodies induced by anti-nicotine vaccine in mice and non-human primates.
    McCluskie MJ; Thorn J; Mehelic PR; Kolhe P; Bhattacharya K; Finneman JI; Stead DR; Piatchek MB; Zhang N; Chikh G; Cartier J; Evans DM; Merson JR; Davis HL
    Int Immunopharmacol; 2015 Apr; 25(2):518-27. PubMed ID: 25737198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent progress in vaccines against nicotine addiction].
    Wang GB; Zhu CJ
    Yao Xue Xue Bao; 2013 Aug; 48(8):1189-94. PubMed ID: 24187824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could a novel vaccine help smokers quit?
    Kuehn BM
    JAMA; 2005 Aug; 294(8):891-2. PubMed ID: 16118374
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccination against nicotine: an emerging therapy for tobacco dependence.
    Maurer P; Bachmann MF
    Expert Opin Investig Drugs; 2007 Nov; 16(11):1775-83. PubMed ID: 17970637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization.
    Zhao Z; Hu Y; Harmon T; Pentel P; Ehrich M; Zhang C
    Biomaterials; 2017 Sep; 138():46-56. PubMed ID: 28551462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
    Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
    J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.
    Hatsukami DK; Rennard S; Jorenby D; Fiore M; Koopmeiners J; de Vos A; Horwith G; Pentel PR
    Clin Pharmacol Ther; 2005 Nov; 78(5):456-67. PubMed ID: 16321612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.